Streetbeat News

ODYY

Odyssey Group Intl Inc

Employees

Industry

Medicinal and Botanical Manufacturing

Open

0.02

Mkt cap

1.5M

Volume

16K

High

0.02

P/E Ratio

0.16

52-wk high

0.16

Low

0.02

Div yield

N/A

52-wk low

0.01

Oragenics is set to acquire Odyssey Health's assets related to its proprietary neurological drug therapies and technologies. The assets include drug candidates for treating mild traumatic brain injury and Niemann Pick Disease Type C, as well as Odyssey's proprietary powder formulation and nasal delivery device. The deal, expected to close in Q4 2023, includes cash payments of $1.0M and 8M shares of Oragenics' Series F Convertible Preferred Stock.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 10:33 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.